Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Amsterdam, Netherlands Clinical Trials

A listing of Amsterdam, Netherlands clinical trials actively recruiting patients volunteers.

RESULTS

Found (37) clinical trials

Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis

Rationale: Natalizumab is an effective drug in the treatment for relapsing remitting multiple sclerosis (RRMS) and is approved in the treatment regimen of 4-weekly 300mg natalizumab infusions. Natalizumab trough concentrations after a 4-weekly interval are high in the large majority of patients which implies a relative overdose in most patients. ...

Phase

0.24 miles

Learn More »

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

This is a randomized-controlled open-label trial comparing two different doses of low-molecular-weight heparin (LMWH) in pregnant patients with a history of previous venous thromboembolism (VTE). Both doses are recommended doses in the 2012 guidelines of the American College of Chest Physicians (ACCP), but it is not known which dose is ...

Phase

0.39 miles

Learn More »

Safety and Efficacy of 6% Hydroxyethyl Starch (HES) Solution Versus an Electrolyte Solution in Patients Undergoing Elective Abdominal Surgery

The aim of the study is to investigate the safety of a 6% HES (Hydroxyethyl Starch) solution (Volulyte 6%) versus an electrolyte solution (Ionolyte) in patients undergoing elective abdominal surgery.

Phase

0.39 miles

Learn More »

Dose Individualization of Pemetrexed - IMPROVE-II

Rationale Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma. Dosing of cytotoxic agents like pemetrexed requires balancing the dual risk of sub-therapy and toxicity. Administration of pemetrexed to patients with a creatinine clearance <45 ml/min is ...

Phase

0.39 miles

Learn More »

Microcirculation Guided Therapy Versus "Standard Treatment" of Severe Sepsis

Despite continued improvements in medical therapy, mortality from septic shock has remained between 30% and 70% for the past three decades with only a slight decrease in mortality rate. Standard treatment of septic shock is fluid resuscitation, followed by agents with vasopressor activity to correct hypotension in septic shock. The ...

Phase

0.81 miles

Learn More »

Mycophenolate Mofetil in Antiretroviral Na ve Patients 2 (MAN2 Study)

*Background: During chronic HIV-1 infection the immune system is chronically hyperactivated. This hyperactivation is considered as the main cause of CD4+ T-cell loss. Furthermore, HIV replicates most efficiently in activated CD4+ T-cells. In this study we try to inhibit the activation of the immune system with mycophenolate mofetil (MMF). Previous ...

Phase

1.13 miles

Learn More »

Switching From Tenofovir Disoproxil Fumarate to Abacavir or Tenofovir Alafenamide

The majority of HIV-1 infected patients in resource rich countries receive the tenofovir prodrug tenofovir disoproxil fumarate (TDF) as part of their combination antiretroviral therapy (cART). Long-term exposure to TDF can be associated with an accelerated estimated glomerular filtration rate (eGFR) decline and proximal renal tubular dysfunction (PTD, see definition ...

Phase

1.13 miles

Learn More »

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.

Phase

2.16 miles

Learn More »

Adalimumab Dose Reduction Aiming Low Serum Concentration With Control of Disease Activity

Biological agents are frequently prescribed to optimize rheumatoid arthritis care. In order to prevent joint destruction it is necessary to maintain remission or low disease activity. Up to now clinicians used to continue the initial treatment regimen to maintain remission or low disease activity. Since biologic therapy is expensive, and ...

Phase

2.16 miles

Learn More »

Adalimumab Drug Optimisation in Rheumatoid Arthritis Using Therapeutic Drug Monitoring

Since the introduction of biologics in rheumatology, as well as treat-to-target (measuring disease activity and adapting treatment accordingly) the prognosis of patients has improved substantially. Obviously, patient burden due to self-injection or infusion, the risk of adverse events and costs demand responsible use of these agents. Multiple studies have shown ...

Phase

2.16 miles

Learn More »